T cell-specific monoclonal antibodies (TABS)
Medigene’s TABS (T cell-specific antibodies) platform utilizes its recombinant TCR technologies in order to produce, isolate and characterize monoclonal antibodies specific for TCR structures. T cell-specific antibodies (TABS antibodies) recognize T cells based on their unique T cell receptors and can therefore distinguish between different T cells expressing different TCRs.
TABS platform allows Medigene to resolve some major challenges in adoptive T cell therapy
TABS antibodies are highly complementary to our TCR technology platform since they can be used to track our TCR-modified T cells both in vitro and in vivo. In the future, they could potentially be applied to precisely control the production of genetically-modified T cells or to remove them after adoptive transfer in patients if adverse effects appear.
TABS platform allows Medigene to identify antibodies against T cell-mediated diseases
As the most sophisticated part of our adoptive immune system, T cells usually protect us from pathogens or malignant cells. However, in some autoimmune diseases such as multiple sclerosis or highly aggressive T cell leukemia, T cells can become pathogenic agents themselves. TABS antibodies can be generated to eliminate those T cells that causes the disease based on their unique TCR structures, allowing the pathogenic or unwanted T cells to be removed while leaving other T cells intact to further provide immunological protection.
T cell specific antibody therapy to remove unwanted T cells
Main advantages of the TABS platform:
- TABS can allow easy control of the T cell products at every step of production.
- TABS represent unique tools to track T cell interactions in patient during clinical use of adoptive T cell therapies.
- TABS address safety and toxicity aspects of adoptive T cell therapies by allowing specific depletion of unwanted T cells.
- TABS may allow causal treatment of T cell-mediated autoimmune diseases and T cell leukemia in the future.
Research status and future projects
Medigene has demonstrated success in isolation of prototype TABS antibody candidates. The functional properties and mode of action of these candidates are currently being tested in vitro and in advanced pre-clinical studies.
In collaborative studies with Prof. Blankenstein of the Max-Delbrück Center (MDC) Berlin using a human TCR-transgenic mouse model, Medigene has shown the elimination of unwanted T cells by prototype TABS based on their TCR expression without affecting other T cells.
Medigene is working intensively on the preparation and functional characterization of TABS antibodies which are intended to monitor all steps in adoptive transfer of genetically-modified T cells from production until application in patients.